Clinical Trials Directory

Trials / Completed

CompletedNCT04355624

Kidney Involvement in COVID-19 Disease (COVKID)

Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study

Status
Completed
Phase
Study type
Observational
Enrollment
45 (actual)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Novel coronavirus disease (COVID-19) is a newly discovered contagious disease caused by SARS-CoV-2 virus, primarily manifesting as an acute respiratory illness with pneumonia, but can affect multiple organs such as kidney, heart, digestive tract, blood and nervous system. In previous reports of SARS and MERS-CoV infections, acute kidney injury was described in 5 to 15% of patients and was associated with a high mortality rate (60-90%). Recent reports showed renal abnormalities in COVID-9 infected patients. A recent Chinese study also reported that acute kidney injury was an independent risk factor for mortality. However, the exact mechanism of kidney involvement remains unclear: sepsis-related cytokine storm or direct cellular injury from the virus. Also, kidney involvement has not yet been well characterized: heavy albuminuria, hematuria or interstitial nephropathy alone. A recent study identified viral RNA in kidney tissue and another study succeeded isolating SARS-CoV-2 from the urine sample of an infected patient. These data suggest that the kidney might be a target of this novel coronarivus. The sponsor suggests characterizing kidney involvement in SARS-CoV-2 infection. Study objectives are: * To give an accurate characterization of kidney involvement in COVID-19 * To investigate the physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection * To identify risk factors for kidney involvement in in SARS-CoV-2 infection * To evaluate the impact of kidney involvement in in SARS-CoV-2 infection * To assess the long-term health effect of kidney injury on survivors of in SARS-CoV-2 infection

Conditions

Timeline

Start date
2020-04-15
Primary completion
2020-04-19
Completion
2020-04-19
First posted
2020-04-21
Last updated
2025-04-03

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04355624. Inclusion in this directory is not an endorsement.